GSK 2282512A
Alternative Names: FLU Q-QIV; FluLaval Quadrivalent; Flulaval Tetra; FLuZactal Tetra; GSK-2282512A; GSK-2833489A; Quadrivalent seasonal influenza vaccine - GlaxoSmithKlineLatest Information Update: 02 Oct 2021
At a glance
- Originator GlaxoSmithKline Biologicals
- Class Antivirals; Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 21 Nov 2016 Registered for Influenza virus infections (Prevention, In infants, In children) in USA (IM)
- 02 Feb 2016 Registered for Influenza virus infections (Prevention, In infants, In children, In adolescents, In adults) in Mexico (IM) before February 2016
- 02 Feb 2016 GlaxoSmithKline files sBLA for inclusion of infants and children aged 6 months to 35 months for Influenza virus infections (Prevention) in USA